Zoetis (NYSE:ZTS – Get Rating) had its price objective dropped by analysts at Citigroup from $232.00 to $208.00 in a research note issued to investors on Wednesday, The Fly reports. Citigroup’s target price would suggest a potential upside of 14.67% from the stock’s current price.
A number of other brokerages also recently commented on ZTS. Morgan Stanley initiated coverage on shares of Zoetis in a report on Thursday, November 18th. They set an “overweight” rating and a $264.00 price target for the company. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 17th. Finally, Zacks Investment Research cut Zoetis from a “buy” rating to a “hold” rating and set a $242.00 target price on the stock. in a report on Saturday, January 8th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $224.78.
Shares of NYSE ZTS opened at $181.39 on Wednesday. The stock has a market cap of $85.61 billion, a price-to-earnings ratio of 42.48, a PEG ratio of 3.34 and a beta of 0.78. Zoetis has a 52 week low of $147.35 and a 52 week high of $249.27. The company’s 50-day moving average price is $202.95 and its 200 day moving average price is $209.84. The company has a current ratio of 3.86, a quick ratio of 2.79 and a debt-to-equity ratio of 1.45.
Zoetis (NYSE:ZTS – Get Rating) last released its quarterly earnings results on Tuesday, February 15th. The company reported $1.00 EPS for the quarter, beating the consensus estimate of $0.96 by $0.04. Zoetis had a net margin of 26.20% and a return on equity of 50.71%. The business had revenue of $1.97 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same period in the prior year, the business earned $0.91 earnings per share. The company’s quarterly revenue was up 8.9% on a year-over-year basis. As a group, research analysts expect that Zoetis will post 5.15 earnings per share for the current year.
In other news, CEO Kristin C. Peck sold 10,000 shares of the business’s stock in a transaction dated Friday, February 25th. The shares were sold at an average price of $192.29, for a total value of $1,922,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 1,315 shares of the company’s stock in a transaction that occurred on Thursday, December 23rd. The shares were sold at an average price of $241.70, for a total value of $317,835.50. The disclosure for this sale can be found here. Insiders sold 45,770 shares of company stock valued at $8,796,480 in the last three months. 0.17% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the stock. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in Zoetis by 12.8% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 87,922 shares of the company’s stock valued at $16,385,000 after buying an additional 9,995 shares during the last quarter. Morgan Stanley grew its position in Zoetis by 4.6% in the 2nd quarter. Morgan Stanley now owns 7,561,487 shares of the company’s stock worth $1,409,158,000 after purchasing an additional 333,952 shares during the last quarter. 1832 Asset Management L.P. increased its stake in shares of Zoetis by 697.9% in the second quarter. 1832 Asset Management L.P. now owns 1,225,267 shares of the company’s stock valued at $229,952,000 after purchasing an additional 1,071,708 shares during the period. Meitav Dash Investments Ltd. bought a new stake in shares of Zoetis during the second quarter valued at approximately $1,066,000. Finally, Thrivent Financial for Lutherans boosted its position in shares of Zoetis by 2.3% during the second quarter. Thrivent Financial for Lutherans now owns 794,351 shares of the company’s stock worth $148,036,000 after buying an additional 17,713 shares during the period. 90.36% of the stock is currently owned by institutional investors and hedge funds.
Zoetis Company Profile
Zoetis, Inc engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers.